Hudson Bay Capital Updates ENVB Stake as of Dec 31, 2023

TL;DR

**Hudson Bay Capital just updated their ENVB holdings, watch for market reaction.**

AI Summary

Hudson Bay Capital Management LP, a hedge fund, filed an amended Schedule 13G/A on February 5, 2024, indicating a change in their ownership of Enveric Biosciences, Inc. (ENVB) common stock as of December 31, 2023. This filing updates their previous disclosure, showing their current stake in the pharmaceutical company. For investors, this matters because it reveals a significant institutional investor's updated position, which can influence market perception and potentially signal confidence or a reduction in interest in ENVB's future prospects.

Why It Matters

This filing provides transparency into a major institutional investor's holdings, offering insight into their current conviction in Enveric Biosciences, Inc. stock.

Risk Assessment

Risk Level: low — This is a routine amendment to a passive ownership filing, indicating a change in a large investor's stake, which is generally not a high-risk event.

Analyst Insight

Investors should monitor subsequent filings from Hudson Bay Capital Management LP for further changes in their Enveric Biosciences, Inc. holdings, as well as Enveric's own financial disclosures, to understand the full context of this updated stake.

Key Players & Entities

• Hudson Bay Capital Management LP (company) — the reporting person and institutional investor
• Enveric Biosciences, Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 5, 2024 (date) — the filing date of the SC 13G/A
• $0.01 (dollar_amount) — par value per share of Enveric Biosciences Common Stock

FAQ

Key Financial Figures

• $0.01 — me of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securitie

Filing Documents

• envb_13ga.htm (SC 13G/A) — 53KB
• image_002.gif (GRAPHIC) — 0KB
• 0001393825-24-000047.txt ( ) — 55KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Enveric Biosciences, Inc., a Delaware corporation (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by Hudson Bay Capital Management LP (the " Investment Manager ") and Mr. Sander Gerber (" Mr. Gerber "), who are collectively referred to herein as " Reporting Persons ."

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

(c)

Item 2(c). CITIZENSHIP: The Investment Manager is a Delaware limited partnership. Mr. Gerber is a United States citizen.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.01 per share (the " Common Stock ").

(e)

Item 2(e). CUSIP NUMBER: 29405E208 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) ¨ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) ý Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) ¨ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentages used in this Schedule 13G are calculated based upon 2,321,315 shares of Common Stock outstanding as of November 30, 2023, as reported in the Company's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on December 6, 2023, and assumes the exercise of the reported warrants. The Investment Manager serves as the investment manager to Hudson Master Fund Ltd., in wh

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATE: February 5, 2024 HUDSON BAY CAPITAL MANAGEMENT LP By: /s/ Sander Gerber Name:Sander Gerber Title:Authorized Signatory /s/ Sander Gerber SANDER GERBER

View Full Filing

View this SC 13G/A filing on SEC EDGAR